Immunocore Holdings Statistics
Immunocore Holdings (6YG) Stock Statistics & Valuation Metrics
Total Valuation
Immunocore Holdings has a market cap or net worth of EUR 1.51B. The enterprise value is EUR 1.10B.
- Market Cap
- EUR 1.51B
- Enterprise Value
- EUR 1.10B
Share Statistics
Immunocore Holdings has 51,681,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 51,681,377
- Owned by Insiders
- 0.04%
- Owned by Institutions
- 25.62%
Financial Efficiency
Immunocore Holdings’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -5.51%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -5.51%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 763.39K
- Profits Per Employee
- -67.77K
- Employee Count
- 524
- Asset Turnover
- 0.37
- Inventory Turnover
- 1.24
Valuation Ratios
The current PE Ratio of Immunocore Holdings is -50.01. Immunocore Holdings’s PEG ratio is 0.62.
- PE Ratio
- -50.01
- PS Ratio
- 3.73
- PB Ratio
- 3.89
- Price to FCF
- -87.97
- Price to Operating Cash Flow
- -156.73
- PEG Ratio
- 0.62
Income Statement
In the last 12 months, Immunocore Holdings had revenue of 400.02M and earned -35.51M in profits. Earnings per share was -0.71.
- Revenue
- 400.02M
- Gross Profit
- 391.66M
- Operating Income
- -45.35M
- Pretax Income
- -19.10M
- Net Income
- -35.51M
- EBITDA
- 520.00K
- Earnings Per Share (EPS)
- -0.71
Cash Flow
In the last 12 months, operating cash flow was -10.41M and capital expenditures -7.79M, giving a free cash flow of -18.20M billion.
- Operating Cash Flow
- -10.41M
- Free Cash Flow
- -18.20M
- Free Cash Flow per Share
- -0.35
Dividends & Yields
Immunocore Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.14%
- Earnings Yield
- -1.97%
Stock Price Statistics
- Beta
- 0.39
- 52-Week Price Change
- -4.00%
- 50-Day Moving Average
- 27.47
- 200-Day Moving Average
- 27.00
- Relative Strength Index (RSI)
- 59.62
- Average Volume (3m)
- 85
Important Dates
Immunocore Holdings upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Immunocore Holdings as a current ratio of 4.04, with Debt / Equity ratio of 114.61%
- Current Ratio
- 4.04
- Quick Ratio
- 4.01
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- -59.66
- Interest Coverage Ratio
- -2.77
Taxes
In the past 12 months, Immunocore Holdings has paid 16.41M in taxes.
- Income Tax
- 16.41M
- Effective Tax Rate
- -0.86
Enterprise Valuation
Immunocore Holdings EV to EBITDA ratio is -887.76, with an EV/FCF ratio of -83.32.
- EV to Sales
- 3.53
- EV to EBITDA
- -887.76
- EV to Free Cash Flow
- -83.32
- EV to Operating Cash Flow
- -145.69
Balance Sheet
Immunocore Holdings has EUR 901.30M in cash and marketable securities with EUR 435.74M in debt, giving a net cash position of EUR 465.56M billion.
- Cash & Marketable Securities
- EUR 901.30M
- Total Debt
- EUR 435.74M
- Net Cash
- EUR 465.56M
- Net Cash Per Share
- EUR 9.01
- Tangible Book Value Per Share
- EUR 8.14
Margins
Gross margin is 98.86%, with operating margin of -6.76%, and net profit margin of -7.48%.
- Gross Margin
- 98.86%
- Operating Margin
- -6.76%
- Pretax Margin
- -3.98%
- Net Profit Margin
- -7.48%
- EBITDA Margin
- -0.40%
- EBIT Margin
- -1.31%
Analyst Forecast
The average price target for Immunocore Holdings is EUR 51.37, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 51.37
- Price Target Upside
- 78.36% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 7.68%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―
